Gsk (GLAXF) Interest Expenses (2009 - 2026)

Gsk's Interest Expenses history runs 18 years deep, the most recent figure standing at -$225.1 million for Q1 2026.

• In Q1 2026, Interest Expenses fell 10.34% year-over-year to -$225.1 million; the TTM figure through Mar 2026 stood at -$1.6 billion (down 9.66% YoY), while the FY2025 annual figure was $924.3 million, up 8.08% from the prior year.
• Interest Expenses was -$225.1 million for Q1 2026 at Gsk, up from -$932.4 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of -$202.7 million in Q3 2024 to a low of -$1.0 billion in Q4 2022.
• Historically, Interest Expenses has averaged -$400.9 million across 5 years, with a median of -$235.7 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Interest Expenses climbed 14.66% in 2024, then retreated 11.76% in 2025.
• A 5-year view of Interest Expenses shows it stood at -$1.0 billion in 2022, then climbed by 4.66% to -$983.0 million in 2023, then grew by 12.65% to -$858.7 million in 2024, then declined by 8.59% to -$932.4 million in 2025, then jumped by 75.85% to -$225.1 million in 2026.
• The last three Interest Expenses figures came in at -$225.1 million (Q1 2026), -$932.4 million (Q4 2025), and -$225.3 million (Q3 2025), per Business Quant data.